End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
38.21 CNY | -0.62% | -5.19% | +9.14% |
May. 14 | Livzon Pharmaceutical Group Cancels Share Options | MT |
May. 14 | Livzon Pharmaceutical Declares Final Dividend for 2023 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.14% | 4.33B | B+ | ||
+37.74% | 723B | C+ | ||
+34.38% | 595B | B | ||
-2.07% | 369B | C+ | ||
+20.25% | 332B | B- | ||
+2.99% | 282B | C+ | ||
+17.00% | 244B | B+ | ||
+9.82% | 208B | B- | ||
-4.42% | 205B | A+ | ||
+2.81% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000513 Stock
- Ratings Livzon Pharmaceutical Group Inc.